
Support for Clinical-Stage Biotech Moving from R&D into a Phase 1 Trial
The transition from research and development into a first-in-human clinical trial is a significant milestone for a biotechnology company. It represents the point at which a candidate therapy moves beyond predominantly exploratory development and enters a highly controlled clinical environment involving human participants, clinical investigators, sponsors, specialist service providers and regulatory oversight.
For a clinical-stage biotech, reaching Phase 1 requires more than promising preclinical results and a viable product candidate. The organisation must demonstrate that its development activities, manufacturing arrangements, quality controls, documentation and clinical operations are sufficiently mature to support the proposed study. Processes that were appropriate for laboratory research may not provide the level of control, traceability and oversight expected when a product is administered to people.
This transition can be particularly challenging for emerging biotechnology companies. They may have a small workforce, limited internal regulatory experience and a quality system that has developed organically alongside their scientific programme. Important activities may have been managed through informal communication, individual expertise or research-focused procedures that are not suitable for clinical trial operations.
Establishing appropriate systems before the first participant is enrolled helps reduce avoidable delays, supports reliable clinical data and provides a stronger foundation for subsequent development.
Understanding the Transition from Research to Clinical Development
Research and development environments are designed to explore scientific questions, generate experimental evidence and evaluate potential therapeutic approaches. Flexibility is often necessary because methods, materials and experimental conditions may change as knowledge develops.
Clinical development introduces additional responsibilities. The sponsor must ensure that the trial is appropriately designed, conducted, monitored, recorded and reported in accordance with applicable requirements. Participant safety and rights must be protected, and the resulting data must be sufficiently reliable to support conclusions about the investigational product.
This does not mean that every research activity must immediately operate under the same requirements as a clinical manufacturing or trial process. Rather, the organisation needs to identify which activities are subject to specific regulatory and quality expectations and establish appropriate controls for each stage of development.
For example, exploratory laboratory research, nonclinical safety studies, investigational product manufacture and clinical trial conduct have different purposes and may be governed by different standards and requirements.
A structured transition plan should identify the activities that will support the Phase 1 programme, assess their current level of control and determine what must be established before clinical trial initiation.
Establishing a Fit-for-Purpose Quality Management System
A quality management system (QMS) provides the framework for managing responsibilities, documented processes, training, records, deviations, corrective actions and change control.
For an early-stage biotech, the objective should be to establish a system that is appropriate to the organisation's size, activities, development stage and risk profile. It should be sufficiently robust to support regulated activities without creating unnecessary administrative complexity.
A common challenge is attempting to build a comprehensive quality system too late in the development programme. When procedures, responsibilities and records are introduced immediately before a clinical milestone, the organisation may struggle to demonstrate consistent implementation.
A more effective approach is to establish core quality processes early and expand them as development activities become more complex.
Key elements commonly include:
Document control and management of approved procedures.
Training records and role-based competency requirements.
Deviation and nonconformance management.
Corrective and preventive action (CAPA).
Change control and impact assessment.
Risk management.
Supplier and service provider qualification.
Internal audit or other planned compliance assessments.
Management oversight and quality review.
The QMS should reflect actual operations. Procedures need to be understandable, responsibilities must be clear and records should demonstrate that processes are being followed.
A system that exists only as approved documents, without evidence of implementation, will not provide effective operational control.
Understanding GMP Requirements for Investigational Products
Good Manufacturing Practice (GMP) is a critical consideration when preparing an investigational medicinal product for clinical use.
The applicable manufacturing requirements depend on the product, jurisdiction, manufacturing activities and clinical development context. Requirements may differ between product types and regions, so organisations should obtain appropriate regulatory and technical advice rather than assume that one manufacturing approach applies to every programme.
For products intended for clinical trials, manufacturing and quality controls must be appropriate to ensure that the investigational product is consistently produced and controlled for its intended use.
This may involve controls over starting materials, manufacturing processes, equipment, facilities, environmental conditions, analytical testing, packaging, labelling, storage and distribution.
The organisation must also consider how manufacturing activities will be documented and how batch records, testing results, deviations and release decisions will be reviewed.
Where manufacturing is outsourced to a contract manufacturing organisation (CMO), the sponsor should establish appropriate oversight and clearly define responsibilities. Outsourcing manufacturing does not remove the need for the sponsor to understand how the product is manufactured and controlled.
Quality agreements and other contractual arrangements can help clarify responsibilities for documentation, deviations, change notifications, investigations, product release and communication of quality issues.
Product Characterisation and Manufacturing Readiness
A clinical candidate must be sufficiently characterised to support its intended clinical use. The level and nature of characterisation depend on the product and its development stage.
For biologics and other complex biotechnology products, relevant considerations may include identity, purity, potency, biological activity, impurities, stability and other product-specific quality attributes.
Manufacturing processes must also be understood to an appropriate extent. Changes in process conditions, raw materials, equipment or manufacturing sites can affect product characteristics. These effects need to be assessed scientifically and managed through appropriate controls.
Process development and manufacturing readiness should therefore be considered together. The organisation should understand which process parameters are important, which attributes require monitoring and what evidence supports the proposed manufacturing approach.
Analytical methods also require suitable development, qualification or validation according to their intended use and applicable requirements. The methods used to assess product quality must be capable of generating reliable information.
A Phase 1 programme does not necessarily require the same process maturity as a commercial manufacturing operation. However, the development-stage approach must still be scientifically justified and compliant with applicable requirements.
Nonclinical Evidence and the Clinical Development Package
Before a first-in-human trial begins, the sponsor must establish an appropriate nonclinical and scientific basis for the proposed clinical investigation.
The nonclinical development programme should address the safety questions relevant to the investigational product, route of administration, proposed dose, treatment duration and intended population. The specific studies required depend on the nature of the product and the applicable regulatory framework.
Relevant evidence may include pharmacology, pharmacokinetics, toxicology and other studies needed to support the proposed clinical approach.
The organisation should ensure that the evidence is appropriately documented, reviewed and available to support regulatory and ethics submissions. Where studies are conducted under Good Laboratory Practice (GLP) requirements, the applicable expectations for study conduct, records and reporting must be addressed.
The clinical development package also needs to bring together information about the investigational product, its manufacture, quality attributes, nonclinical findings and proposed clinical use.
The Investigator's Brochure and other trial documents should provide investigators with relevant information about the product and its known or potential risks. The content must be consistent with the available evidence and maintained as development progresses.
Preparing for ICH Good Clinical Practice
Good Clinical Practice (GCP) provides an internationally recognised ethical and scientific quality standard for clinical trial design, conduct, recording and reporting.
ICH E6(R3) reinforces the importance of participant protection, reliable trial results, quality by design and proportionate, risk-based approaches to trial oversight. Sponsors should understand the requirements applicable in the jurisdictions where their studies will be conducted.
For an emerging biotech, preparation for GCP responsibilities should begin before the trial starts. The company must understand its sponsor obligations and establish appropriate oversight of investigators, clinical research organisations (CROs), laboratories, vendors and other service providers involved in the study.
Important areas include:
Clear assignment of sponsor responsibilities.
Selection and oversight of qualified investigators and trial sites.
Appropriate trial monitoring and risk management.
Management of safety information and reporting obligations.
Control of essential trial documents and records.
Reliable collection, processing and review of clinical data.
Management of protocol deviations and significant compliance issues.
Appropriate arrangements for trial close-out and record retention.
A CRO may perform delegated activities, but the sponsor retains responsibility for ensuring that delegated trial activities are appropriately managed and overseen.
The sponsor should understand what work has been delegated, how performance will be monitored and how important issues will be escalated.
Building a Reliable Clinical Trial Documentation System
Clinical development generates substantial documentation. Records must support reconstruction of important trial activities and provide evidence that the study was conducted according to the protocol, applicable requirements and approved procedures.
Essential documents may include the protocol, Investigator's Brochure, informed consent documentation, regulatory and ethics approvals, investigator qualifications, monitoring records, safety reports and trial-specific agreements.
The sponsor should establish a controlled approach to document preparation, review, approval, distribution, storage and retention.
Electronic systems may support document management and clinical data handling, but their use requires appropriate governance. System access, user responsibilities, data security, audit trails, backup arrangements and system suitability should be considered according to the intended use and applicable requirements.
Data integrity is fundamental. Information should be attributable, legible, contemporaneous, original and accurate, with additional expectations for completeness, consistency, endurance and availability.
Research teams moving into clinical development may need to strengthen their practices for recording decisions, maintaining traceability and controlling electronic records. These changes should be introduced in a planned manner rather than left until the trial is underway.
Supplier and CRO Oversight
Small biotechnology companies commonly rely on external providers for activities they cannot reasonably maintain in-house. These may include GMP manufacturing, analytical testing, clinical monitoring, pharmacovigilance, data management, biostatistics and regulatory support.
External expertise can be valuable, but effective oversight remains essential.
The organisation should assess potential providers according to the activities they will perform and the risks associated with those activities. Relevant considerations may include technical capability, relevant experience, quality systems, regulatory history, capacity and the ability to meet the programme's requirements.
Responsibilities should be documented through suitable agreements and procedures. The company should understand how service providers manage deviations, changes, data, records and quality concerns.
Communication arrangements are particularly important. A sponsor must be able to identify problems affecting the trial or investigational product and ensure that they are addressed within appropriate timeframes.
Supplier oversight should be proportionate to risk, but it should never become a substitute for understanding the outsourced activity.
Managing Change as the Programme Develops
Biotechnology development is rarely static. Scientific findings, manufacturing experience, stability data and clinical observations may lead to changes in the product, process, analytical methods or clinical programme.
Changes need to be assessed before implementation. A formal change control process helps determine whether a proposed modification could affect product quality, participant safety, regulatory submissions, validated systems, trial documentation or previously generated data.
Some changes may require additional testing, qualification, validation or regulatory and ethics review. The precise requirements depend on the nature of the change and the applicable jurisdiction.
The organisation should maintain traceability between the development history, manufacturing records and clinical documentation. This is particularly important when process or product changes occur during early clinical development.
A well-managed change process supports scientific progress while ensuring that decisions remain documented, justified and appropriately reviewed.
Developing Internal Capability Before the First Participant
A clinical-stage biotech does not necessarily need a large internal quality department. It does, however, need sufficient knowledge and capability to understand its obligations, oversee critical activities and make informed decisions.
Key personnel should understand the quality and regulatory requirements relevant to their responsibilities. This may include founders, executives, research leaders, quality personnel, regulatory specialists, manufacturing representatives and clinical operations staff.
Training should be role-specific and supported by appropriate records. Personnel involved in GMP activities require relevant GMP instruction, while those involved in clinical trial conduct need appropriate GCP training and an understanding of their assigned responsibilities.
Training should also address the organisation's own procedures and systems. General awareness of regulatory standards is not enough if employees cannot apply the requirements to their actual work.
Where specialist activities are outsourced, internal personnel still need enough knowledge to assess provider performance, review outputs and recognise when a concern requires escalation.
Building this capability reduces dependence on external parties for routine quality decisions and helps preserve organisational knowledge as the company grows.
Creating a Practical Phase 1 Readiness Plan
Preparing for Phase 1 should be managed as a coordinated programme involving scientific, clinical, quality, manufacturing and regulatory functions.
A practical readiness assessment can identify gaps between current operations and the requirements for the planned trial. This assessment should consider the investigational product, manufacturing arrangements, nonclinical evidence, regulatory strategy, clinical documentation, service providers and internal competency.
The resulting plan should assign responsibilities, establish realistic timelines and identify dependencies. Critical activities should be prioritised according to their potential impact on participant safety, product quality, regulatory approval and trial readiness.
Management should review progress regularly and ensure that unresolved issues are escalated. Readiness should be supported by objective evidence, including approved procedures, completed training, appropriate agreements, controlled records and documented assessments.
Importantly, the company should avoid treating the first participant visit as the only measure of success. A well-prepared Phase 1 programme must also be capable of maintaining oversight, responding to emerging information and managing the study through completion.
Supporting the Move into Clinical Development
Moving from R&D into a Phase 1 trial requires a change in organisational capability. Scientific innovation remains central, but it must be supported by appropriate quality systems, regulatory understanding, controlled manufacturing, reliable documentation and effective clinical oversight.
For emerging biotechnology companies, the challenge is to establish these capabilities without introducing unnecessary complexity or diverting resources from essential development activities.
Quality Systems Now supports therapeutic goods manufacturers, biotechnology organisations and testing laboratories in strengthening their quality systems and developing practical internal capability. This includes helping organisations understand GxP expectations, identify gaps, improve procedures and prepare their people for the responsibilities associated with regulated activities.
The most effective preparation begins before clinical trial initiation. By addressing quality, compliance and operational readiness early, a biotech can approach its first-in-human programme with clearer responsibilities, stronger controls and a more reliable foundation for clinical development.
